Myeloma

The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.

I reflect on finding peace, purpose and presence after my diagnosis through a creative writing exercise rooted in mindfulness and metaphor.

I share how I survived multiple myeloma, painful spine fractures and years of recovery to reclaim my independence and vitality.

I challenged a mistaken fall risk label before my transplant and proved that self-advocacy is crucial to both quality care and emotional well-being.

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma

Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles.

CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.

Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.

Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.

A panel of experts discussed the transition of care between community and academic centers at the CURE Educated Patient Multiple Myeloma Summit.

Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.

Dr. Joseph Mikhael discusses early signs, treatments and supportive care for multiple myeloma in an interview with CURE.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

I rediscovered myself through community, writing, music and cooking after my journey with multiple myeloma.

Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.

After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.

2024 was a year of resilience after a myeloma diagnosis, marked by a return to public speaking, a documentary filming experience and a fundraising walk.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

As we near the end of 2024, CURE is looking back at the top FDA approval stories of the year.

Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a Darzalex treatment combination.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Updated data from the phase 3 DREAMM-7 trial was presented during the 2024 ASH Annual Meeting and Exposition.

Tecvayli alone or plus Revlimid has been found to be safe and may result in high MRD-negativity rates.

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with smoldering multiple myeloma.

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd improved MRD responses as well as progression-free survival.